Jasper Therapeutics beats Q2 expectations but shares fall after results
Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.
How this was made
The 30-second read
Why it matters
The key trade tension is a fundamental beat (smaller adjusted loss) versus investor concern about execution across an enlarged pipeline, despite runway extension into 2028.
Market read
Traders should focus on how the market is pricing pipeline execution risk after the Kira deal, using the stated cash runway and the next clinical/regulatory milestones as near-term anchors.
What to watch
The article does not quantify how Kira integration changes probability of success or trial timelines, so the selloff may be driven by uncertainty not captured in the reported cash runway.
Background
Jasper is a clinical-stage biotech that expanded its pipeline via an all-stock acquisition of Kira Pharmaceuticals in July and raised $132M through a private placement.
Ticker impact
Jasper reported an adjusted Q2 loss of $0.10 per share versus a $0.28 consensus, but shares fell 4.24% pre-market after the results and Kira deal update.
Near-term volatility likely persists as investors weigh runway extension into 2H 2028 against upcoming clinical and regulatory milestones.
The article provides both the earnings beat and the immediate negative pre-market reaction, plus concrete next catalysts (KP-104 interim data in Q4 2026, briquilimab pre-BLA steps in Q1 2027, KP-701 CTA in Q1 2027).
Market effects
Biotech investors may continue to favor cash runway clarity and near-term clinical readouts over headline EPS beats.
Limited, US-focused small/mid-cap biotech sentiment spillover possible.
Low; primarily company-specific clinical and financing news.
Counterpoint
The adjusted-loss beat plus runway into 2H 2028 could be underappreciated, making the pre-market dip a potential re-rating opportunity ahead of KP-104 interim data.
Key entities
- companyJasper Therapeutics Inc.
Reported better-than-expected Q2 adjusted loss, completed Kira acquisition, and raised $132M to fund operations into 2H 2028.
- companyKira Pharmaceuticals
Acquired by Jasper in July via an all-stock transaction to broaden immune-mediated disease pipeline.
- regulatorU.S. Food and Drug Administration (FDA)
Briquilimab is moving toward a pre-BLA meeting, with next-step details expected in Q1 2027.
